Company Performance Metrics
- Raj Mehta: Team MemberPast Role: GammaDelta Therapeutics, Interim CEO
Deborah Harland: Non Executive DirectorPast Role: Bicycle Therapeutics, Non Executive Director
Cancer Research Horizons develops and commercialises exciting new discoveries in cancer research. They’re the meeting point between academia and industry. Their deep understanding of both perspectives enables them to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return.
CRT is
uniquely placed to capitalise on the research and connections of theirr parent organisation Cancer Research UK, the world’s largest charitable funder of cancer research and the strong links they’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide.
CRT has 30 years’ specialist experience in the commercialisation of cancer research and a proven track record of successful innovation.
CRT personnel are experienced, dedicated and highly motivated with an average length of service of nearly 6 years. The workforce is split between drug discovery and commercialisation for a comprehensive approach to getting breakthrough therapeutics to patients.
